Tag Archives: panel

RESI Boston Summer 2018 Panel Announcement: Corporate Venture Capital

24 May

By Cole Bunn, Director of Research, LSN

cole-wp

Large corporations, especially in the pharmaceutical/biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation, an exit partner; however, attracting and concentrating talent, providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

This increasingly important investor class will discuss trends in the space, their current interests and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by Reza Halse, President, MRL Ventures, this panel will feature:

By registering for RESI Boston, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

Tags: , ,

RESI on MaRS Panel Announcement: Diagnostics Investors

29 Mar

By Claire Jeong, Research Analyst, LSN

claire

The field of diagnostics can be a difficult space to navigate due to challenges in the regulatory and reimbursement processes that hinder successful commercialization. However, the implications of diagnostic technologies can be enormous; from precision genomics that enable optimum health management and personalized care to novel biomarkers that can successfully detect high mortality diseases in its earliest stages, diagnostics companies are developing some of the most highly disruptive technologies in the industry.

In this session, we invite 5 investors with strong expertise in this diverse space to speak about their unique approaches in working with early-stage companies. Investors will discuss the types of investment opportunities they seek and share valuable insights on building long lasting relationships, differentiating your technology from similar competitors, and more. We hope you will be able to join us for the RESI Toronto Conference in the MaRS Innovation Center on April 10th to meet these awesome panelists!

Moderated by Drew Taylor, Lead Medical Researcher, Epic Capital Management, the panel participants are:

  • Yiu-Lian Fong, Innovation Lead for Diagnostics, Johnson & Johnson (Medical Devices)
  • Kelly Holman, Co-Founder & Managing Director, Genesys Capital
  • Yvan Côté, General Manager of Dynacare Next & Orchid PRO-DNA, Dynacare
  • Amine Benmoussa, Principal (Healthcare), BDC Healthcare Fund

 

Tags: , , , , ,

RESI on MaRS Panel Announcement: Corporate Venture Capital

22 Mar

By Cole Bunn, Director of Research, LSN

cole-wp

Large corporations, especially in the pharmaceutical and biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation – an exit partner. However, attracting and concentrating talent, and providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

Toronto, looking to ramp up commercialization of its world-class research and put its name on the map as a life science powerhouse, will host the RESI conference for the third time as a part of the Toronto Health Innovation Week and welcome a panel of Corporate Venture investors. This increasingly important investor class will discuss trends in the space, their current interests, and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by Salim Teja, President, Venture Services, MaRS Discovery District, this panel will feature:

  • Marian Nakada, VP of Venture Investing, Johnson & Johnson
  • Jens Eckstein, President, SR One
  • Richard Osborn, Managing Partner, TELUS Ventures
  • Tom Gibbs, Director, Debiopharm Innovation Fund

By registering for RESI on MaRS, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

Tags: , , , , ,

RESI on MaRS Panel Announcement: Medical Device Investors

22 Mar

By Lucy Parkinson, VP of Investor Research, LSN

Medical device innovation is known for being a challenging area for raising capital.  Given the timelines and capital requirements involved, as well as the increasing consolidation of the major firms that make up the exit landscape for devices, entrepreneurs may find it difficult to build their investment story.  However, LSN is in contact with hundreds of investors who are seeking deals in the device space, either for purely return-driven investments or for adding to a strategic pipeline.  At RESI, we aim to bridge the gap between early stage device firms and investors and help entrepreneurs close those ‘last three feet’ to make deals.

At RESI on MaRS, we welcome a Medical Device Investors panel featuring experienced investors from across North America, including both strategic players and financially-driven venture investors who will explore and elucidate the world of early stage device investment from every angle.  The panel will be moderated by Sam Ifergan, President & CEO, iGan Partners, and the participants are:

  • Katherine Parra Moreno, Vice President of Business Development, Epic Capital Management
  • Zishan Haroon, Chairman and General Partner, Julz Co LLC
  • V Kadir Kadhiresan, Vice President, Venture Investments, Johnson & Johnson Innovation
  • Gerry Brunk, Managing Director, Lumira Capital

Tags: , , , , ,

RESI San Francisco @ JPM Week – Medical Devices Panel Announcement

14 Dec

By Claire Jeong, Research Analyst, LSN

claire

With RESI San Francisco less than a month away, we are proud to announce the Medical Device investors panel, where 5 seasoned experts in medical device investments will discuss how they seek to work with early-stage medical technology entrepreneurs.

The fundraising process and path to commercialization for medical device products continue to be a rigorous challenge for many budding companies. Especially with the exponential growth of the IoT/IoMT market, a growing number of entrepreneurs are focusing on the development of connected, “smarter” devices that incorporate a software or data component. Although often overshadowed by the biopharmaceutical industry in terms of degree of need or financial returns, the medical device sector is a very much needed area in the improvement of healthcare.

If you are a medical device entrepreneur and heading to San Francisco for JPM week, you do not want to miss out on our RESI Medical Devices panel! Our panelists are:

  • Renee Ryan, Vice President, JJDC, Johnson & Johnson Innovation (JLABS)
  • Yao Li Ho, Director of Business Development, LYFE Capital
  • Zishan “Z” Haroon, Chairman & General Partner, Julz Co LLC
  • Sam Ifergan, President & CEO, iGan Partners
  • Randy Scott, Partner, HealthQuest Capital

Tags: , , , , ,

RESI New York City: Venture Philanthropy Panel Announcement

2 Nov

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

Venture philanthropic foundations have deep expertise that is often overlooked. Each foundation has a specific, genuine mission towards a disease area that provides them enormous capacity to bring forward more than any entrepreneur can realize. Along with funding, venture philanthropic investors can provide patient access for underserved populations, specialize in assessing and tracking “positively impactful” technology in their particular field, and utilize their own relationships with traditional ventures in creative ways, among other initiatives.

New York City is home to a great number of life science foundations. LSN has dedicated the Venture Philanthropy panel to the following five incredible Foundations for the RESI New York City Conference on November 15th. Moderated by John Walter, CEO and President of Alliance for Cancer Gene Therapy, the audience will have an exclusive opportunity to hear from:

  • Alyssa Reimer, Associate Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson’s Research
  • Michael Batten, Director, Strategic Partnerships, Juvenile Diabetes Research Foundation (JDRF) T1D Fund
  • Ken LaMontagne, VP of Research, Therapy Acceleration Program, Leukemia & Lymphoma Society
  • Andres Hurtado-Lorenzo, Director of Translational Research, Crohn’s and Colitis Foundation

Venture philanthropy investors maintain the genuine purpose of moving forward in the field of life science. Non-traditional investors such as these groups are great funding sources with incredible knowledge in their fields, while also taking inspirational strides to achieve their goals.

Foundations are a strong reminder not to lose track of the mission in life science.

Register before it’s too late to hear first-hand from this fantastic panel!

Tags: , , , ,

RESI San Diego Panel: Corporate Venture Capital

1 Jun

By Lucy Parkinson, Director of Research, LSN

Corporate venture capital funds have been a key pillar of the life science investment community for some time, and at LSN we’ve seen these groups evolving on strategy to keep up with an increasingly competitive investor marketplace. While many pharma firms still use corporate VC as a strategic vehicle for filling pipelines, these firms are increasingly collaborative and keen to be seen as aligned with the interests of entrepreneurs and other investors, as well as those of their parent companies.

At RESI, a panel of 5 top corporate VCs from around the world will explain how their group makes strategic investments in early stage companies, and how a corporate VC relationship can help a startup company get ahead in development and strategic relationships.

Moderated by Rajeev Dadoo (Partner, SR One), the participants are:

Tags: , , , ,

← Older Entries

%d bloggers like this: